Parkinson's Flashcards

1
Q

List the different anti-parkinsonian drugs and their modes of action.

A

D2 receptor agonists:
Bromocriptine, pergolide (Ergot)
Ropinirole, rotigotine (non-ergot)

MAO-B Inhibitors
Selegiline, Rasagiline

COMT inhibitors
Sinemet, Madopar

L-DOPA: Bypasses L-tyrosine in synthesis pathway.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the 4 degeneration mechanisms in parkinsons?

A
  1. Ubiquitin proteasome pathway disruption
  2. ROS- Mitochondrial abnormalities cause uncoupling of redox reactions- ROS generation. SN in Parkinson’s may be deficient in antioxidants e.g glutathione.
  3. Neuroinflammation: Microglial activation. Neurotoxins can activate microglia. (indirect, mixed mode & direct neurotoxins)
  4. Mitochondrial dysfunction. Inner membrane integrity lost. Release of cytochrome c.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Which TFs are implicated in controlling neuronal vulnerability during development?

A
  1. Nurr1. (maintains neurotransmitter levels)
  2. FoxA2: KO mice lost neurons in SN only.
  3. Engrailed: All DA neurons lost without 4 alleles.

Therefore, vulnerability is exposed through reduced developmental TF expression and loss likely mediated through mitochondrial dysfunction.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the difference in vulnerability between SN & VTA neurons?

A

SN neurons more vulnerable. VTA neurons express more G substrate, & other protective TFs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Which gene mutations are present in PD?

A

Alpha-synuclein: Normally involved in synaptic vesicle function. Hyperphosphorylated & Ubiquitinated in Lewy bodies. Misfolded form toxic to neurons?

Parkin: E3 ligase, addition of ubiquitin to proteins. Loss of parkin->failure to break down damaged proteins

Pink-1: Targets to mitochondria. KO causes mito dysfunction, reduced respiratory chain activity, reduced ATP in tissues.

DJ1: Targeted to mitochondria. Inhibits a-synuclein aggregation via chaperone activity. Modulates mitochondrial membrane potential & enhances energetics.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the disease correlates of the following neuropathological markers?

A

a-synuclein
Tau
TDP-43
Non specific

Vascular
Toxic
Drug Induced
Infectious

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Why are SN neurons physiologically less vulnerable than VTA DA neurons?

A

SN neurons are involved in movement- pacemaker like properties. This involves frequent intracellular calcium transients, which isn’t buffered, making them prone to neurodegeneration.

VTA neurons have no transients, less Ca2+ density, high calbindin to protect cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the 6 braak stages in parkinsons?

A

1: Olfactory bulb, Dorsal motor nucleus
2: Locus coeruleus & Raphne. Sublaterodorsal nucleus.
3 & 4: SNc, pars compacta, Basal forebrain.
5 & 6: Invades neocortex, spreads into different lobes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the 5 genes that are altered in parkinson’s?

A
  1. Synuclein
  2. LRRK2 (interacts with parkin)
  3. Parkin (E3 ligase, tags proteins. Mitochondria turnover)
  4. PINK1 (protects cells from stress induced mitochondrial dysfunction- induces autophagy)
  5. FJ-1 (redox sensitive chaperone, stabilises mito membrane potential)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the normal function of a-synuclein & what happens when it is dysregulated?

A

Involved in SNARE complex formation and neurotransmitter release.

Without synuclein, vesicles not released and become trapped- neurotransmitter leaks (dopamine) which oxidises. This causes free radicals.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What negative effects does unfolded a-synuclein have?

A

Proteasome function
Mitochondria complex I inhibition
Autophagy inhibition
Membrane transition pore more leaky.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is LRRK2 involved in and what is the most common mutation?

A

Mitochondrial function, inflammation, lysosome function, trafficking, autophagy/mitophagy, neurite growth and differentiation.

Most common mutation is G2019S.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is GBA and which drugs target it?

A

Encodes glucocerebrosidase (GCase), which hydrolyses glucosylceramide into ceramide and glucose (breaks down lysosomes).

Ambroxole
Venlustat

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

List some risk loci (SNPs)

A
MAPT
SNCA
BST1
LRRK2
ACMSD
STK39
HIP1R
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the role of epigenetics in neurodegeneration?

A

Chromatin packaging determines accessibility of genome. More acetylation means more transcription.

In neurodegeneration, the balance is shifted to HDACs, so less transcription.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Which epigenetic changes are seen in parkinson’s?

A

DNA methyltransferases (DNMT1) : translocated out of nucleus in PD- results in hypomethylation.

Histone modification: a-synuclein promotes histone H3 hypoacetylation (masks H3)

17
Q

What is an example of an HDAC inhibitor?

A

Valproate: Causes changes in histone acetylation

18
Q

What is lactacystein and how was it used with valproate?

A

Lactacystein: Inhibits proteasome and induces neurodegeneration. Associated with histone hypoacetylation and reduced gene expression- causes lesions in mice.

Valproate with lactacystein lesion:
Neuroprotection seen with low dose valproate, high dose showed reversal of cell loss.

19
Q

What are the 3 toxin based rodent models?

A

6-OHDA
MPT
Lactacystein

20
Q

How does 6-OHDA work?

A

Induce oxidative stress and mitochondrial inhibition, iron accumulation and inflammation.

Dose responsive loss of nigrostriatal pathways.

21
Q

How does MPTP work?

A

Lipophilic, penetrates BBB. Mitochondrial inhibition + Oxidative stress. No protein inclusions.

Loss of DA neurons in the nigra, VTA neurons intact.

Only effective in non human primates- causes akinetic, flexed posture, rigidity, clumsiness and tremor. MPTP converted to MPP+ in the primate brain.

22
Q

How does the proteasome inhibitor lactacystein work?

A

Causes chronic progressive, nigral cell loss and inclusions. It causes lesions.

23
Q

Describe some a-synuclein animal models.

A

Drosophila:
Few neurons and high turnover rate (easy to examine)
Selective neuronal death
Flies show ‘movement disorder’

Mice over-expressing wild type synuclein
Single mutation- no pathology.
2 mutations- pathology. Less stress and strains in mouse system so needs 2 mutations to set it off.

rAAV-a-synuclein model
rAAV viral vector transfects neurons to overproduce wild type a-synuclein. Loss of DA striatal terminals and cell bodies.
Deficits in motor behaviour

Pre formed fibrils
a-synuclein fibrils injected into striatum form inclusions
Cause native a-synuclein to misfold, and spread across brain with time.

24
Q

How have iron chelators been used as a treatment?

A

Collects iron in the brain and removes it. Clinical trial in 2020.

Chelation therapy successful in B-thalassaemia (iron overload)

25
Q

What are the 3 parkinson’s plus disorders?

A

Multiple system atrophy
Corticobasal degeneration
Progressive supranuclear palsy

26
Q

What are the 2 subtypes of MSA, and describe microscopic and macroscopic features.

A

MSA-P (predominant parkinsonism)
MSA-C (cerebellar)

Microscopic:
Mixed neuronal and glial pathology
Glial cytoplasmic inclusions
Oligodendroglial inclusions- (Papp Lantos Bodies)

Macroscopic:
Cortico and cerebellar atrophy
Shrinkage of middle cerebellar peduncle, pons and inferior olivary nucleus
Loss of locus coeruleus and SN neurons.

27
Q

What are the features of corticobasal degeneration?

A

Rigidity, stiffness, jerking of arm.
Cerebral cortex, deep cerebellar nuclei and SN affected.

Microscopic:
Glial and neuronal inclusions
Neutropil threads prominent
Astrocytic plaques and balloon neurons.

28
Q

What are the features of progressive supranuclear palsy?

A

Most common form of atypical parkinsonism.
Supranuclear gaze palsy, postural instability.
Atrophy of basal ganglia, subthalamus, brainstem.

Microscopic:
Neuronal and glial pathology
Tufted astrocytes and coiled bodies.

29
Q

What are the 2 subtypes of Tau, and what is its function?

A

3R or 4R Tau.

Binds and stabilises microtubules. Increased phosphorylation = less MT binding. Promotes microtubule polymerisation.

30
Q

How could you identify biomarkers and image diagnose parkinson plus disorders?

A

Biomarkers: Look at protein profiles in CSF, develop algorithms to differentiate MSA and other a-synucleinopathies.

Imaging: PET & MRI show different activation patterns in MSA, PSP and CBD.